Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

Randox announces CE Marking of its Sexually Transmitted Infection (STI) Multiplex Array

Published: Wednesday, November 28, 2012
Last Updated: Wednesday, November 28, 2012
Bookmark and Share
Randox is pleased to announce the CE marking of the STI Multiplex Array, recognising its use as a powerful diagnostic weapon in the battle to control sexually transmitted infections.

Sexually transmitted infections (STIs) are on the increase worldwide and present a major challenge to world public health.  This rise in STI cases shows that current measures, including existing technologies and screening programmes cannot cope with clinical need. STIs are of significant medical, social and economic importance affecting up to 25-30% of young adults, with the developing world having a disproportionate burden of disease. STIs can be difficult to diagnose because of atypical or asymptomatic presentation and left untreated can result in serious health problems including infertility or complications during pregnancy.  Those with untreated STIs can also act as reservoirs for future infection.

To avoid preventable health complications and to encourage more responsible sexual health practices, Randox has developed the STI Multiplex Array that can simultaneously detect 10 of the most prevalent STIs from a single urine or swab sample, in a single test within 5 hours. These STIs include Chlamydia trachomatis, Neisseria gonorrhoea, Trichomonas vaginalis, Treponema pallidum (syphilis), Herpes simplex 1 & 2, Mycoplasma hominis, Mycoplasma genitalium, Ureaplasma urealyticum and Haemophilus ducreyi.


In addition to providing the most comprehensive STI screen available, testing for multiple STI pathogens can identify secondary infections, which are present in greater numbers than previously thought, and allow specific treatments for all infections diagnosed.  The accuracy and comprehensive diagnostic ability of the Randox STI Multiplex Array compensates for many of the current diagnosing limitations and has the potential to revolutionise STI diagnosis. This will improve patient outcome and reduce the social and economical burden of such pathogens. Using this test has added benefits through more appropriate use of antibiotics, which will reduce the potential for antibiotic resistance.

The CE marking of the STI Multiplex Array signifies that this groundbreaking test is suitable for the accurate diagnosis of STIs in a clinical setting and provides further evidence that Randox continues to develop innovative diagnostic solutions to meet the increasing demands of healthcare providers worldwide.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Potential Persistent Tuberculosis Treatment
Researchers have discovered several first-in-class compounds that target hidden TB infections by attacking a critical process the bacteria use to survive in the hostile environment of the lungs.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
The Do’s and Don’ts of SPR Experiments
Surface Plasmon Resonance (SPR) is a technique that is becoming more widely used, particularly by anyone who wants to obtain accurate on (association) and off (dissociation) rates for biomolecular binding.
Long-Sought Protein Sensor for the ‘Sixth Sense’ Discovered
In a study led by scientists from The Scripps Research Institute (TSRI)the sensor protein for propioception has been identified.
New Anti-Malarial Drug Screening Model
University of South Florida researchers demonstrate novel chemogenomic profiling to identify drug targets for the most lethal strain of malaria.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.
New, Better Test for Prostate Cancer
A study from Karolinska Institutet shows that a new test for prostate cancer is better at detecting aggressive cancer than PSA.
Giant Molecules Inhibit Ebola Infection
European researchers have designed a "giant" molecule formed by thirteen fullerenes covered by carbohydrates which, by blocking this receptor, are able to inhibit the cell infection by an artificial ebola virus model.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos